UBS Downgrades Standard Life to Neutral, Citing Valuation After 25% Rally

UBS has downgraded its rating on Standard Life to "Neutral" from "Buy," citing the stock's strong year-to-date performance. Analysts at the bank said in a note on Tuesday that a more than 25% rise in the insurer's shares this year has largely factored in the anticipated benefits from future capital actions.

Valuation and Price Target

Despite the downgrade, UBS raised its price target on Standard Life to 1,015 pence from 995 pence. The bank noted that the shares' valuation now appears fair after outperforming both its UK life insurance peers and the broader European insurance sector. The new price target is compared to the stock's closing price of 940 pence on August 28.

Cash Generation and Returns

UBS maintains a positive outlook on Standard Life's cash generation and shareholder returns. The bank anticipates the company will announce recurring annual share buybacks of approximately £200 million at its capital markets day on November 30. This contributes to an expected all-in shareholder yield of about 9% by 2028.

The note forecasts cumulative total cash generation of £6.3 billion over the 2027-2029 period, significantly above the consensus estimate. This optimistic forecast is driven by:

Ad

• The acquisition of Aegon's UK business, expected to contribute roughly £900 million in cash generation during that timeframe.
• The newly launched PRT Solutions business, which could add another £100 million to £200 million.

Balance Sheet Considerations

Looking ahead, UBS expects Standard Life to report a negative IFRS shareholder equity position of about £200 million in its first-half results on September 7. The bank warned this could face further pressure from higher UK interest rates and equity market movements.

While this negative equity position is not expected to restrict shareholder distributions, UBS noted it could weigh on demand from generalist investors. However, the bank views Standard Life's balance sheet as resilient, forecasting its Solvency II ratio will rise to about 185% by 2030, which is above the company's target operating range of 140%-180%.